Qiagen this week announced that it has launched the Therascreen IDH1/2 RGQ kit in Europe and other certain markets after the test received CE marking.

The test is based on Qiagen's proprietary biomarkers for IDH1 and IDH2 gene mutations, and enables detection of 12 such mutations using real-time PCR. It is designed to enable physicians to better diagnose and assess the prognoses of patients with gliomas, or tumors of the brain and spinal cord.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.